Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma

NCT00073983 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

54

Enrollment

OTHER

Sponsor class

Conditions

Sarcoma

Interventions

BIOLOGICAL: filgrastim
BIOLOGICAL: pegfilgrastim
DRUG: docetaxel
DRUG: gemcitabine hydrochloride
GENETIC: microarray analysis
OTHER: laboratory biomarker analysis
OTHER: pharmacokinetic study

Sponsor

Sarcoma Alliance for Research through Collaboration